Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this multicenter Phase II trial, researchers found that topical GT20029 significantly increased hair regrowth in Chinese adult males with androgenetic alopecia compared to placebo, demonstrating good tolerability and suggesting the need for further studies to confirm its therapeutic potential.

This article reviews the potential for α-difluoromethylornithine to help control hair growth and prevent cancer, but it does not present new clinical results.

This study found that 54% of participants with androgenetic alopecia using Ricapil® showed clinical signs of hair follicle reactivation and initial hair regrowth over three months.

This study found that a synthetic avicequinone C analogue, 5e, was significantly more potent in inhibiting steroid 5α-reductase type 1 activity in human keratinocytes compared to the original isolated compound.

This study found that intradermal injection of a specially designed RNA molecule, cp-asiAR, successfully reduced androgen receptor levels and promoted hair growth in a mouse model of androgenetic alopecia, while also improving hair follicle characteristics in ex vivo human scalp tissues without significant toxicity.

This study found that 4-MA is a potent inhibitor of testosterone 5α-reductase in human tissues, promising potential for treating androgen-dependent skin conditions like male pattern baldness.

This study reports that combination therapies, including surgical and various medical treatments, show promise for managing androgenetic alopecia, though further research is necessary to confirm the safety and effectiveness of emerging therapies.

This article provides an overview of current treatments and alternative formulations for androgenic alopecia but reports no new clinical results.

This source suggests that oral minoxidil could be a safe and effective treatment option for both female and male androgenetic alopecia, although it is currently used off-label.

In mouse studies, this research found that combining ginsenoside Rg3 and glycyrrhizic acid with minoxidil improved treatment outcomes for androgen alopecia by addressing both symptoms and root causes, notably activating the Wnt/β-catenin pathway and promoting hair follicle cell proliferation.

This article outlines the synthesis of spiro[cyclohexane‐1,2′‐[2 H ]indene] derivatives similar to known steroid 5α‐reductase inhibitors, but it does not report experimental findings.

In a study using an AGA mouse model, researchers observed that a novel topical gel combining hybrid extracellular vesicles, gold nanoparticles, and finasteride accelerated hair regrowth and improved hair quality more effectively than conventional minoxidil treatment, presenting a promising option with fewer side effects.

This review highlights that nanocarrier-based formulations, using both synthetic drugs and natural components, show promise in overcoming the limitations of current androgenetic alopecia treatments with modified release profiles and enhanced drug delivery, though clinical trials remain limited.

This study reports that Hair RiseTM microemulsion, made from plant extracts, significantly enhanced hair follicle cell growth and improved hair growth signaling pathways, suggesting it as a plant-based alternative for androgenetic alopecia treatment.

Hyaluronic acid microneedles help deliver minoxidil derivatives effectively for hair regrowth.

This review discusses recent advances in understanding the molecular mechanisms of androgenic alopecia and developments in its pharmacotherapy, with a focus on factors influencing hair follicle regeneration in genetically predisposed individuals.

This study described the development and evaluation of a finasteride nanogel for treating androgenetic alopecia, reporting higher cumulative drug release and enhanced spreadability compared to a plain gel, suggesting potential as a treatment option.

This case report discusses a 32-year-old man's treatment for advanced androgenetic alopecia using a combination of topical minoxidil and oral finasteride, but no clinical outcomes are detailed.

This article discusses trichoscopy as a tool for differential diagnosis in female-type androgenetic alopecia and reports on three patient cases without providing new clinical results.

This study observed that patients using a novel topical combination of finasteride and minoxidil for male androgenetic alopecia reported high satisfaction and good tolerance, with few side effects and no need for higher-level care, despite limitations such as retrospective data and no control group.

This study found that forsythoside A, a compound from Forsythia suspensa, may counteract DHT-induced hair regrowth inhibition by selectively inhibiting TRPV3 channels.

This review discusses recent advances in the understanding of androgenetic alopecia, focusing on genetic factors and new diagnostic and treatment approaches, but it does not provide new clinical results.

This study reviewed early research on topical finasteride for androgenetic alopecia, finding it appears safe and promising, though further investigation is needed to determine optimal dosing, frequency, and potential applications for other types of alopecia.

This review discusses the use of dutasteride for treating androgenetic alopecia and reports no new clinical results.

This study found that a combined oral contraceptive containing ethinyl estradiol and desogestrel appeared effective in temporarily treating ovarian hyperandrogenism in adolescents, with reductions in hormone levels and ovarian volume observed.

This abstract provides no research findings; it is just information about the JAMA Dermatology journal's website and access options.

This study found that specific steroids, particularly 5 and 7b, decreased growth of prostate and seminal vesicles and bound to the androgen receptor, showing comparable pharmacological activity to finasteride.

This study reviewed the literature on Minoxidil and finasteride for androgenetic alopecia, finding both drugs effective but noting potential side effects, with combined therapy possibly enhancing efficacy and patient adherence while reducing adverse effects.

This phase 1 study reported that after administering supratherapeutic doses of cortexolone 17α‐propionate, a topical antiandrogen intended for hair loss treatment, there was no effect on the QTc interval, indicating no measurable cardiac safety concerns in the concentration range tested.

This report suggests that for prostate cancer patients with cardiovascular disease, prescribing the GnRH antagonist degarelix may reduce cardiac events compared to using GnRH agonists, although prescribing should consider potential cardiac risks, particularly in patients with pre-existing conditions or older age.